Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société POXEL
10/16Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the Frenc..
AQ
10/15POXEL : Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French..
BU
10/11POXEL : Corporate Presentation - English
PU
10/07POXEL : Corporate Presentation - English
PU
10/02POXEL : Announces Positive Results from Phase 2a NASH Trial with PXL770, an Oral..
AQ
10/01POXEL : Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral..
BU
09/25Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-..
AQ
09/24POXEL : Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-R..
BU
09/22Poxel Announces Participation at Upcoming Scientific and Investor Conferences
AQ
09/22POXEL : 2020 Half Year Financial Report
PU
09/21POXEL : Corporate Presentation - English
PU
09/21POXEL : Announces Participation at Upcoming Scientific and Investor Conferences
BU
09/16Poxel Reports Financial Results for First Half 2020 and Provides a Corporate ..
AQ
09/15POXEL : 1H 2020 Financial and Corporate Presentation
PU
09/15POXEL : Reports Financial Results for First Half 2020 and Provides a Corporate U..
BU
09/03POXEL : to Host Conference Call for First Half 2020 Financial Results on Septemb..
BU
09/02POXEL : Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Pat..
BU
08/06POXEL : Corporate Presentation - English
PU
07/30POXEL : Announces Submission of Imeglimin Japanese New Drug Application for the ..
BU
07/21POXEL : Provides Corporate Update and Reports Cash and Revenue for the Second Qu..
BU
07/07POXEL : Corporate Presentation - English
PU
06/25POXEL : Announces Results from June 24, 2020 Ordinary Annual and Extraordinary G..
BU
06/25POXEL : Announces Positive Pharmacokinetic Pharmacodynamic Study Results for PXL..
AQ
06/24POXEL : Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Res..
BU
05/28POXEL : Announces Participation in Upcoming Virtual Investor Conferences
BU
05/26Poxel Successfully Raises EUR17.7 Million in a Capital Increase
AQ
05/25POXEL : Announces Program Update and Preclinical Results on PXL770 for NASH Comb..
BU
05/25POXEL : Successfully Raises €17.7 Million in a Capital Increase
BU
05/18POXEL : Announces Notice of its Annual General Meeting to be Held on June 24, 20..
BU
04/21POXEL : Announces First Quarter 2020 Financial and Corporate Update
BU
04/20POXEL : Announces Publication of Imeglimin Clinical Study Results in Clinical Ph..
BU
04/20POXEL : Announces Availability of 2019 Universal Registration Document and Provi..
BU
03/26POXEL : Reports Financial Results for Full Year 2019 and Provides Corporate Upda..
BU
03/23POXEL TO HOST CONFERENCE CALL FOR FU : 30 pm EDT
BU
03/04POXEL : to Report Full Year 2019 Financial Results and Host Conference Call on M..
BU
02/12POXEL : Reports Financial Update for Cash and Revenue for the Full Year 2019 and..
BU
02/12POXEL : Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd ..
BU
01/23POXEL : Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer
BU
01/08POXEL : Announces its Financial Calendar for 2020
BU
2019Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results..
AQ
2019POXEL : and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results ..
BU
2019POXEL : Announces Participation at ODDO BHF Forum
BU
2019POXEL : Announces Positive Results for PXL065 Phase 1b Trial and Provides Progra..
BU
2019POXEL : Announces Updates to its Management Team
AQ
2019POXEL : Announces Positive Topline Results for Imeglimin Phase 3 Trial for the T..
AQ
2019POXEL : and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results ..
PU
2019POXEL : Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Tr..
PU
2019POXEL : Announces its Financial Calendar for 2019
PU
2018POXEL : Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and P..
PU
2016POXEL : Closes a €26.5 Million Capital Increase
PU
2016POXEL : Appoints Janice Bourque and Pierre Legault to its Board of Directors
PU
2016POXEL : Provides YE15 Cash and Turnover Figures
PU